Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 9/20 | 1.00 |
| ▸ | MAPT | P10636 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29416813 | 1.00 | KAT2B (1.00) | KAT2BMAPTALDH1A1LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL513245 | 0.99 | KAT2B (1.00) | KAT2BMAPTALDH1A1LMNAKMT2A | |
| SCHEMBL14981759 | 0.88 | KAT2B (0.97) | KAT2BMAPTPKM | |
| Hydrochloric Acid SCHEMBL513348 | 0.87 | KAT2B (1.00) | KAT2BMAPTPOLBPKM | |
| SCHEMBL14906561 | 0.85 | KAT2B (0.74) | KAT2BMAPTALDH1A1LMNAKMT2A | |
| SCHEMBL29580274 | 0.85 | KAT2B (0.74) | KAT2BMAPTALDH1A1POLBPKM | |
| SCHEMBL4858189 | 0.85 | KAT2B (0.74) | KAT2BMAPTALDH1A1POLBPKM | |
| SCHEMBL4863416 | 0.84 | KAT2B (0.72) | KAT2BMAPTALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL16151564 | 0.84 | KAT2B (0.72) | KAT2BMAPTALDH1A1LMNAKMT2A | |
| SCHEMBL10622798 | 0.84 | KAT2B (0.72) | KAT2BMAPTALDH1A1POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-02-16 | — | — | US | disclosed |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-09-16 | — | — | US | disclosed |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-08-05 | — | — | US | disclosed |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2021-07-29 | — | — | US | disclosed |
| US-20120028912-A1 | Methods of modulating bromodomains | J.David Gladstone Institute | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028912-A1 | Methods of modulating bromodomains | BAZ2A, BRPF3, BRD3 | KAT2B 37/4885MAPT 1884/4885ALDH1A1 3591/4885 |
| US-20210238226-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ATXN2L, ATXN2, ATXN10 | KAT2B 36/4885MAPT 446/4885ALDH1A1 4306/4885 |
| US-20210283265-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | KAT2B 2513/4885MAPT 598/4885ALDH1A1 4642/4885 |
| US-20230050819-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | CYFIP2, TPX2, ATXN2 | KAT2B 645/4885MAPT 1976/4885ALDH1A1 4788/4885 |
| US-20210228723-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | ZFX, F13B, GRN | KAT2B 735/4885MAPT 3487/4885ALDH1A1 4687/4885 |
| US-20210284629-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, UBQLN2, UBTF | KAT2B 1273/4885MAPT 301/4885ALDH1A1 4592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.